SynCore Biotechnology Co.,Ltd
4192
Rank in Stocks
#27109
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the... SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Share Price
$0.47555756
Last synced: 2026-11-10
Market Cap
$16.72M
Change (1 day)
-5.74%
Change (1 year)
-44.69%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade SynCore Biotechnology Co.,Ltd (4192)
Category
Healthcare
Operating Margin for SynCore Biotechnology Co.,Ltd (4192)
Operating Margin as of November 2026 TTM: -194.10%
According to SynCore Biotechnology Co.,Ltd's latest financial reports, its current operating margin (TTM) is -194.10%. At the end of 2025 the company had an operating margin of -174.52%.
Operating Margin history for SynCore Biotechnology Co.,Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -194.10% | 11.22% |
| 2025 | -174.52% | -29.48% |
| 2024 | -247.49% | 9.85% |
| 2023 | -225.30% | -80.83% |
| 2022 | -1,175.47% | -82.13% |
| 2021 | -6,579.65% | 121.84% |
| 2020 | -2,965.90% | -7.68% |
| 2019 | -3,212.67% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.20% |
US
|
|
| -149.01% | -99.23% |
US
|
|
| 25.57% | -100.13% |
AU
|
|
| 31.23% | -100.16% |
BE
|
|
| 29.35% | -100.15% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about SynCore Biotechnology Co.,Ltd's operating margin
What is SynCore Biotechnology Co.,Ltd's operating margin?
SynCore Biotechnology Co.,Ltd's operating margin is -194.10%, as of Nov 2026.
What was SynCore Biotechnology Co.,Ltd's operating margin in 2025?
In 2025, SynCore Biotechnology Co.,Ltd's operating margin was -174.52%, compared with -247.49% in 2024.
How has SynCore Biotechnology Co.,Ltd's operating margin changed since 2020?
From 2020 to 2025, SynCore Biotechnology Co.,Ltd's operating margin was highest in 2025 (-174.52%) and lowest in 2021 (-6,579.65%).
How does SynCore Biotechnology Co.,Ltd's operating margin compare with similar companies?
SynCore Biotechnology Co.,Ltd's operating margin (-194.10%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.